Bacterial contamination of platelet components: Potential solutions to prevent transfusion-related sepsis

Expert Review of Hematology

Volumn 4, Issue 5, 2011, Pages 509-525

  Corash, Laurence ^a,b  

^a CERUS CORPORATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bacteria; pathogen inactivation; pathogen reduction; platelet components; transfusion related sepsis

Indexed keywords

PLATELET COMPONENT; THROMBOCYTE CONCENTRATE; UNCLASSIFIED DRUG;

BACILLUS; BACTERIUM; BACTERIUM CONTAMINATION; BACTERIUM CULTURE; BACTERIUM DETECTION; BIFIDOBACTERIUM; CLINICAL PRACTICE; CLOSTRIDIUM; CORYNEBACTERIUM; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; HUMAN; KLEBSIELLA PNEUMONIAE; LACTOBACILLUS; LISTERIA MONOCYTOGENES; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROPRIONIBACERTRIUM; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA CHOLERAESUIS; SEPSIS; SERRATIA MARCESCENS; STAPHYLOCOCCUS; STREPTOCOCCUS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TRANSFUSION RELATED SEPSIS; YERSINIA ENTEROCOLITICA;

BACTERIA; BACTERIAL INFECTIONS; BLOOD PLATELETS; DISINFECTION; FICUSIN; HUMANS; NUCLEIC ACIDS; PLATELET TRANSFUSION; PSORALENS; RIBOFLAVIN; RISK FACTORS; SEPSIS; ULTRAVIOLET RAYS;

EID: 80053194901     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.11.53     Document Type: Review

References (91)

1. Yomtovian R. Bacterial contamination of blood: lessons from the past and road map for the future. Transfusion 44, 450-460 (2004). (Pubitemid 38365524)
2. Blajchman MA, Beckers EAM, Dickmeiss E, Lin L, Moore G, Muylle L. Bacterial detection of platelets: current problems and possible resolutions. Transfus. Med. Reviews 19, 259-272 (2005). (Pubitemid 41415653)
3. Braine HG, Kickler TS, Charache P et al. Bacteria sepsis secondary to platelet transfusion: an adverse effect of extended storage at room temperature. Transfusion 26, 391-393 (1986). (Pubitemid 16056287)
4. Department of Health and Human Services, CBER. Reduction of the maximum platelet storage period to 5 days in an approved container. US FDA, Bethesda, MD, USA (1986).
5. Jacobs MR, Good CE, Lazarus HM, Yomtovian RA. Relationship between bacterial load, species, virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clin. Infect. Dis. 46, 1214-1220 (2008). (Pubitemid 351589905)
6. Eder AF, Kennedy JM, Dy BA et al. Limiting and detecting bacterial contamination of apheresis platelets: inlet-line diversion and increased culture volume improve component safety. Transfusion 49, 1554-1563 (2009).
7. Murphy WG, Foley M, Doherty C et al. Screening platelet concentrates for bacterial contamination: low numbers of bacteria and slow growth in contaminated units mandate an alternative approach to product safety. Vox Sang. 95, 13-19 (2008). (Pubitemid 351799415)
8. Pearce S, Rowe GP, Field SP. Screening of platelets for bacterial contamination at the Welsh Blood Service. Transfus. Med. 21, 25-32 (2010).
9. Dumont LJ, Kleinman S, Murphy JR et al. Screening of single-donor apheresis platelets for bacterial contamination: the PASSPORT study results. Transfusion 50, 589-599 (2010).
10. Burger R, Offergeld R. Stipulation of the shelf-life of thrombocyte concenteates with the aim of reducing life-threatening transfusion reactions as a result of bacterial contamination. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 38, 1884 (2008).
11. Pietersz RNI, Engelfriet CP, Reesink HW et al. Detection of bacterial contamination of platelet concentrates. Vox Sang. 93, 260-277 (2007). (Pubitemid 47373995)
12. Yomtovian R, Tomasulo P, Jacobs MR. Platelet bacterial contamination: assessing progress and identifying quandries in a rapidly evolving field. Transfusion 47, 1340-1346 (2007). (Pubitemid 47101092)
13. Yomtovian RA, Palavecino EI, Dysktra AH et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion 46, 719-730 (2006).
14. Blajchman MA, Thornley JH, Richardson H, Elder D, Spiak C, Racher J. Platelet transfusion-induced Serratia marcescens sepsis due to vacuum tube contamination. Transfusion 19, 39-44 (1979). (Pubitemid 9169550)
15. Blajchman MA, Goldman M. Bacterial contamination of platelet concentrates: incidence, significance, and prevention. Semin. Hematol. 38 (Suppl. 11), 20-26 (2001).
16. Walther-Wenke G, Schrezenmeier H, Deitenbeck R et al. Screening of platelet concentrates for bacterial contamination: spectrum of bacteria detected, proportion of transfused units, and clinical follow-up. Ann. Hematol. 89(1), 83-91 (2009).
17. Blajchman MA, Goldman M, Baeza F. Improving the bacteriological safety of platelet transfusions. Transfus. Med. Rev. 18, 11-24 (2004). (Pubitemid 38018800)
18. Schrezenmeier H, Walther-Wenke G, Muller TH et al. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 47, 644-652 (2007). (Pubitemid 46449625)
19. Walther-Wenke G, Wirsing von Konig CH, Daubener W et al. Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures. Vox Sang. 100(4), 359-366 (2010).
20. Benjamin RJ, Wagner SJ. The residual risk of sepsis: modeling the effect of concentration on bacterial detection in two-bottle culture systems and an estimation of false-negative culture rates. Transfusion 47, 1381-1389 (2007). (Pubitemid 47101084)
21. Lee CK, Ho PL, Lee KY. Estimation of bacterial risk in extending the shelf-life of PLT concentrates from 5 to 7 days. Transfusion 43, 1047-1052 (2003). (Pubitemid 37022363)
22. de Korte D, Cuvers J, de Kort WL. Effects of skin disinfection method, deviation bag, and bacterial screening on clinical safety of platelet transfusions in the Netherlands. Transfusion 46, 476-485 (2006). (Pubitemid 43334104)
23. Nussbaumer W, Allersdorfer D, Grabmer C et al. Prevention of transfusion of platelet components contaminated with low levels of bacteria: a comparison of bacteria culture and pathogen inactivation methods. Transfusion 47, 1125-1133 (2007). (Pubitemid 46934306)
24. Brecher ME, Hay SN. Investigation of an isolate of Staphylococcus lugdunensis implicated in a platelet fatality: a possible advantage of the use of an anaerobic bottle. Transfusion 47, 1390-1394 (2007). (Pubitemid 47101083)
25. Macauley A, Chandrasekar A, Geddis G. Operational feasibility of routine bacterial monitoring of platelets. Transfus. Med. 13, 189-195 (2003). (Pubitemid 36950556)
26. Munksgaard L, Albjerg L, Lillevang ST, Gahrn-Hansen B, Georgsen J. Detection of bacterial contamination of platelet components: six years' experience with the BactT/ALERT system. Transfusion 44, 1166-1173 (2004). (Pubitemid 38989749)
27. Te Boekhorst PAW, Beckers EAM, Vos MC, Vermeij H, Rhenen DJ. Clinical significance of bacteriologic screening in platelet concentrates. Transfusion 45, 514-519 (2005).
28. Hanna H, Raad I. Blood products: a significant risk factor for long-term catheter-related bloodstream infections in cancer patients. Infect. Control Hosp. Epidemiol. 22, 165-166 (2001). (Pubitemid 32233896)
29. Duggan J, O'Connell D, Heller R, Ghosh H. Causes of hospital-acquired septicaemia - a case control study. QJ Med. 86, 479-483 (1993). (Pubitemid 23239383)
30. Greco C, Mastronardi C, Pagotto F, Mack D, Ramirez-Arcos S. Assessment of biofilm-forming ability of coagulase-negative staphylococci isolated from contaminated platelet preparations. Transfusion 48(5), 969-977 (2008). (Pubitemid 351614908)
31. Greco C, Martincic I, Gusinjac A, Kalab M, Yang AF, Ramirez-Arcos S. Staphylococcus epidermidis forms biofilms under simulated platelet storage conditions. Transfusion 47, 1143-1153 (2007). (Pubitemid 46934308)
32. Martin-Rabadan P, Gijon P, Alcala L, Rodriguez-Creixems M, Alvarado N, Bouza E. Propionibacterium acnes is a common colonizer of intravascular catheters. J. Infect. 56, 257-260 (2008).
33. Rao PL, Strausbaugh LJ, Liedtke LA, Srinivasan A, Kuehnert MJ; Infectious Disease Society of America Emerging Infections Network. Bacterial infections associated with blood transfusion: experience and perspective of infectious disease consultants. Transfusion 47, 1206-1211 (2007). (Pubitemid 46934321)
34. Eder AF, Kennedy JM, Dy B et al. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross Experience (2004-2006). Transfusion 47, 1134-1142 (2007). (Pubitemid 46934307)
35. Niu MT, Knippen M, Simmons L, Holness LG. Transfusion-transmitted klebsiella pneumoniae fatalities, 1995-2004. Transfus. Med. Rev. 20, 149-157 (2006).
36. Heal JM, Jones ME, Forey J, Chaudhry A, Stricof RL. Fatal Salmonella septicemia after platelet transfusion. Transfusion 27, 2-5 (1987). (Pubitemid 17030025)
37. Rhame FS, Root RK, MacLowry JD, Dadisman TA, Bennett JV. Salmonella septicemia from platelet transfusions: study of an outbreak traced to hematogenous carrier of Salmonella cholerae-suis. Ann. Int. Med. 78, 633-641 (1973).
38. Jafari M, Forsberg J, Gilcher RO et al. Salmonella sepsis caused by a platelet transfusion from a donor with a pet snake. N. Engl. J. Med. 347, 1075-1078 (2002).
39. Andreu G, Morel P, Forestier F, Rebibo D, Janvier G, Herve P. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994-1998. Transfusion 42, 1356-1364 (2002).
40. Kientz D, Waller C, Mendel I, Laforet M, Isola H, Cazenave JP. The frequency of transfusion-related sepsis imputed to platelet components: impact of pathogen inactivation. Presented at: 13th International Haemovigilance Seminar. Amsterdam, The Netherlands, 9-11 February 2011.
41. McCullough J, Vesole DH, Benjamin RJ et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial. Blood 104, 1534-1541 (2004). (Pubitemid 39166535)
42. TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N. Engl. J. Med. 337, 1861-1869 (1997).
43. Chiu EKW, Yuen KY, Lie AKW et al. A prospective study of symptomatic bacteremia following platelet transfusion and of its management. Transfusion 34, 950-954 (1994). (Pubitemid 24373766)
44. Kuehnert M, Roth V, Haley NR et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 41, 1493-1499 (2001). (Pubitemid 34072672)
45. Stormer M, Kleesiek K, Dreier J. Propionibacterium acnes lacks the capability to proliferate in platelet concentrates. Vox Sang. 94, 193-201 (2008). (Pubitemid 351379656)
46. Perry AL, Lambert PA. Propionibacterium acnes. Lett. Appl. Microbiol. 42, 185-188 (2006).
47. Clayton JJ, Baig W, Reynolds GW, Sandoe JA. Endocarditis caused by Propionibacterium species: a report of three cases and a review of clinical features and diagnostic difficulties. J. Med. Microbiol. 55, 981-987 (2006). (Pubitemid 44215554)
48. Hinestrosa F, Djurkovic S, Bourbeau PP, Foltzer MA. Propionibacterium acnes as a cause of prosthetic valve aortic root abscess. J. Clin. Microbiol. 45, 259-261 (2007). (Pubitemid 46106443)
49. Zeller V, Ghorbani A, Strady C, Leonard P, Mamoudy P, Desplaces N. Propionibacterium acnes: an agent of prosthetic joint infection and colonization. J. Infect. 55, 119-124 (2007). (Pubitemid 47029748)
50. Schneider T, Breviere D, Taillefer MF, Pujol-Rey A, Huart JJ. Bacterial contamination of platelet concentrates by Propionibacterium acnes. Transfus. Clin. Biol. 7, 540-546 (2000). (Pubitemid 32052448)
51. McDonald CP, Lowe O, Roy A et al. Evaluation of donor arm skin disinfection techniques. Vox Sang. 80, 135-141 (2001). (Pubitemid 35339932)
52. McDonald C, McGuane S, Thomas J et al. A novel rapid and effective donor arm disinfection method. Transfusion 50, 53-58 (2010).
53. Benjamin RJ, Dy B, Warren R, Lischka M, Eder AF. Skin disinfection with a single-step 2% chlorhexidine swab is more effective than a two-step povidone-iodine method in preventing bacterial contamination of apheresis platelets. Transfusion 51(3), 531-538 (2010).
54. Jenkins C, Ramirez-Arcos S, Goldman M, Devine DV. Bacterial contamination in platelets: incremental improvements drive down but do not eliminate risk. Transfusion DOI: 10.1111/j.1537-2995.2011.03187.x. (2011) (Epub ahead of print).
55. de Korte D, Marcelis JH, Verhoeven AJ, Soeterboek AM. Diversion of first blood volume results in a reduction of bacterial contamination for whole-blood collections. Vox Sang. 83, 13-16 (2002). (Pubitemid 36806493)
56. Muller TH, Mohr H, Montag T. Methods for the detection of bacterial contamination in blood products. Clin. Chem. Lab. Med. 46, 933-946 (2008).
57. Jacobs MR, Good CE. Residual bacterial contamination of apheresis platelets following early culture-results of a multi-site study of 18,449 units using the Verax Pan Genera Detection assay. Transfusion 50, 30A (2010).
58. Yazer MH, Stapor D, Triulzi DJ. Use of the RQI test for bacterial screening of whole blood platelets. Am. J. Clin. Pathol. 133, 564-568 (2010).
59. Vollmer T, Engemann J, Kleesiek K, Dreier J. Bacterial screening by flow cytometry offers potential for extension of platelet storage: results of 14 months of active surveillance. Transfus. Med. 21, 175-182 (2011).
60. Pietersz RN, Engelfriet CP, Reesink HW. Detection of bacterial contamination of platelet concentrates. Vox Sang. 85, 224-239 (2003). (Pubitemid 37247809)
61. Golding B. 510(k) Summary Basis of Approval: Platelet PGD Test System. In: Center for Biologics Evaluation and Research. FDA, Rockville, MD, USA (2009).
62. Holme S, McAlister MB, Ortolano GA et al. Enhancement of a culture-based bacterial detection system (eBDS) for platelet products based on measurement of oxygen consumption. Transfusion 45, 984-993 (2005). (Pubitemid 40798791)
63. McDonald CP, Pearce S, Wilkins K et al. Pall eBDS: an enhanced bacterialdetection system for screening platelet concentrates. Transfus. Med. 15, 259-268 (2005). (Pubitemid 41633114)
64. Savini V, Balbinot A, Giancola R et al. Comparison between the BACTEC 9240 and the Pall eBDS system for detection of bacterial platelet concentrate contamination. Transfusion 49, 1217-1223 (2009).
65. Larsen CP, Ezligini F, Hermansen NO, Kjeldsen-Kragh J. Six years' experience of using the BactT/ALERT system to screen all platelet concentrates, and additional testing of outdated platelet concentrates to estimate the frequency of false-negative results. Vox Sang. 88, 93-97 (2005). (Pubitemid 40362924)
66. Walther-Wenke G, Doerner R, Montag T et al. Bacterial contamination of platelet concentrates prepared by different methods: results of standardized sterility testing in Germany. Vox Sang. 90, 177-182 (2006).
67. Dreier J, Stormer M, Pichl L et al. Sterility screening of platelet concentrates: questioning the optimal test strategy. Vox Sang. 95, 181-188 (2008).
68. Barbara J. The rationale for pathogen inactivation treatment of platelet components - introduction. Semin. Hematol. 38(Suppl. 11), 1-3 (2001). (Pubitemid 33096552)
69. Mohr H, Steil L, Gravemann U et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 49, 2612-2624 (2009).
70. Lin L, Dikeman R, Molini B et al. Photochemical treatment of platelet concentrates with amotosalen and UVA inactivates a broad spectrum of pathogenic bacteria. Transfusion 44, 1496-1504 (2004). (Pubitemid 39318986)
71. Osselaer JC, Doyen C, Defoin L et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 49, 1412-1422 (2009).
72. Cazenave JP, Isola H, Waller C et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3 year period. Transfusion 51(3), 622-629 (2010).
73. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Semin. Hematol. 38(Suppl. 11), 4-11 (2001). (Pubitemid 33096553)
74. Lin L, Cook DN, Wiesehahn GP et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37, 423-435 (1997). (Pubitemid 27193557)
75. Stormer M, Vollmer T, Kleesiek K, Dreier J. Spore-forming organisms in platelet concentrates: a challenge in transfusion bacterial safety. Transfus. Med. 18, 371-376 (2008).
76. Snyder E, Raife T, Lin L et al. Recovery and Lifespan of 111 Indium radiolabeled platelets treated with pathogen inactivation using amotosalen HCl (S-59) and UVA light. Transfusion 44, 1732-1440 (2004).
77. Lozano M, Knutson F, Tardivel R et al. A multi-center study of therapeutic efficacy and safety of platelet components prepared with pathogen inactivation (INTERCEPT) stored for 6 or 7 days prior to transfusion. Br. J. Haematol. DOI: 10.1111/j.1365-1241.2011.08635.x. (2011) (Epub ahead of print).
78. van Rhenen D J, Gulliksson H, Cazenave JP et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 101, 2426-2433 (2003). (Pubitemid 36302092)
79. Kerkhoffs JL, van Putten WL, Novotny VMJ et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solutions with and without pathogen reduction. Br. J. Haematol. 150, 209-217 (2010).
80. Corash L, Sherman CD. Evaluation of platelet transfusion clinical trials. Br. J. Haematol. 153(4), 529-531 (2011).
81. Snyder E, McCullough J, Slichter SJ et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 45, 1864-1875 (2005). (Pubitemid 43971413)
82. Corash L, Lin JS, Sherman CD, Eiden J. Determination of acute lung injury following repeated platelet transfusions. Blood 117, 1014-1020 (2011).
83. Osselaer JC, Cazenave JP, Lambermont M et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang. 94, 315-323 (2008). (Pubitemid 351535733)
84. Osselaer JC, Messe N, Hervig T et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 48, 1061-1071 (2008). (Pubitemid 351793479)
85. Cazenave JP, Osselaer JC, Waller C et al. An active hemovigilance program utilizing and EDC system to assess safety of 2994 plasma transfusions prepared with the INTERCEPT Blood System. Transfusion 48, 29A (2008).
86. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard L, Goodrich RP. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 44, 877-885 (2004). (Pubitemid 38738418)
87. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plssma: an overview of current status and future trends. Transfus. Apheresis. Sci. 35, 5-17 (2006). (Pubitemid 44354317)
88. Kumar V, Lockerbie O, Keil SD et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochem. Photobio. 80, 15-21 (2004).
89. Goodrich RP, Gilmour D, Hovenga N, Keil SD. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 49, 1205-1216 (2009).
90. Cazenave JP, Follea G, Bardiaux L et al. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 50, 2362-2375 (2010).
91. Arbeitskreis Blut. Mindestanforderungen zur sterilitatstestung von blutkomponenten. 23. Sitzung des Arbeitskreis Blut am. Bundegesundheitsblatt 8, 307-309 (1997).